Startups
Edit
Defence Therapeutics Inc.
https://defencetherapeutics.com/Last activity: 17.02.2025
Probably Closed
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company developing and engineering the next generation of radio-immuno-conjugate and ADC products using its proprietary platform in addition to novel immune-oncology vaccines. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of radio-immuno-conjugates or ADCs in their intact form to target cells, and vaccine antigens. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
Visit Website
Visit Website
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 16
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Feb 3, 2023 | Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors | Vancouver, British Columbia--(Newsfile Corp. - February 3, 2023) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncol... |
| Jan 24, 2023 | Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated | Vancouver, British Columbia--(Newsfile Corp. - January 24, 2023) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncol... |
| Jan 23, 2023 | RETRANSMISSION: Defence to Present at the 9th Annual Immuno-Oncology 360º Summit in New-York February 7-10, 2023 | Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncol... |
| Dec 20, 2022 | Breakthrough Results: Defence's Novel AccuTOX(TM) Intranasal Reduced 50% of Cancer Nodules on Animals with Lung Tumors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2022) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-onco... |
| Nov 23, 2022 | Defence's Successfull Study on the AccuVAC-PT007 Vaccine Targeting Cervical Cancer | Vancouver, British Columbia--(Newsfile Corp. - November 23, 2022) - Defence Therapeutics Inc. DTC DTC DTCFF ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-onco... |
| Jan 26, 2022 | Defence Therapeutics Inc.: Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 | DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous Defence Therapeutics Inc.: Defence's AccumTM-HPV vaccine formulation (AccuVAC-PT009) activates a 36-fold higher humoral response compared to Gardasil-9 26.01.2022 / 08:30 The... |
| Nov 30, 2021 | DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT | DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT 30.11.2021 / 08:30 The issuer is solely responsible for the content of this announcement. CSE: DTC FSE: DTC USOTC: DTCFF... |
| Nov 23, 2021 | DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER | DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS CANCER VACCINE ACCUVAC-D001 MANUFACTURING TARGETS MELANOMA AND BREAST CANCER 23.11.2021 / 08:30 The issuer is solely responsible for the content of this ... |
| Oct 19, 2021 | Defence Therapeutics Scores Again With New Planned Phase 1 Trial Evaluating Its DC Cancer AccuVAC-D002 Against Melanoma | Defence Therapeutics (OTC Pink: DTCFF) has reached a second milestone in as many weeks after announcing they are close to finalizing the required processes ahead of a pre-IND meeting to initiate a Phase I trial evaluating its DC cancer vacc... |
Show more
Reviews 0
FAQ about Defence Therapeutics Inc.
What has the press written about Defence Therapeutics Inc.?
Parsers VC has collected 16 articles mentioning Defence Therapeutics Inc., among them “Defence Manufacturing Its Arm Vaccine in Preparation for Phase I Clinical Trial Against Solid Tumors” (Feb 3, 2023) and “Defence's Melanoma Targeted Vaccine A1-Reprogrammed MSC (ARM) Cell Potency Validated” (Jan 24, 2023).
Is Defence Therapeutics Inc. still active?
Defence Therapeutics Inc. is probably closed: its latest activity on Parsers VC dates from Feb 17, 2025.